NS-304Selexipag , 99%, single miscellaneous <0.1% , 475086-01-2

CAS NO.：475086-01-2

Empirical Formula: C26H32N4O4S

Molecular Weight: 496.62

MDL number: MFCD10567093

PRODUCT Properties

• Melting point: 134-138°C
• Density: 1.210±0.06 g/cm3(Predicted)
• storage temp.: -20°C Freezer
• solubility: DMSO (Slightly), Methanol (Slightly)
• pka: 3.82±0.40(Predicted)
• form: Solid
• color: Pale Yellow
• InChIKey: QXWZQTURMXZVHJ-UHFFFAOYSA-N
• SMILES: C(NS(C)(=O)=O)(=O)COCCCCN(C1=NC(C2=CC=CC=C2)=C(C2=CC=CC=C2)N=C1)C(C)C

Description and Uses

Selexipag and its active metabolite, the corresponding carboxylic acid, are nonprostanoid prostaglandin I2 (PGI-2) receptor agonists. The N-methylsulfonamide within selexipag is hydrolyzed to the corresponding carboxylic acid in vivo by hepatic microsomes at a rate which provides a slow-release pharmacological effect. The compound was originally discovered by Nippon Shinyaki and later licensed to Actelion for development. The drug was approved in 2015 and first launched for the oral treatment of pulmonary arterial hypertension (PAH) in the U.S. in 2016 to delay disease progression and reduce the risk of hospitalization.

Selexipag is an orally available, highly selective, long-acting prostacyclin (IP) receptor agonist prodrug. It is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319
• Precautionary statements: P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313